Factor | Training group (n = 162) | Test group (n = 140) | ||||
---|---|---|---|---|---|---|
95% CI | RR | p | 95% CI | RR | p | |
Sex (male vs. female) | 0.43–1.41 | 0.78 | 0.40 | 0.75–3.41 | 1.60 | 0.22 |
Age (≤ 60 y vs. >  60 y) | 0.73–2.06 | 1.23 | 0.44 | 0.83–2.80 | 1.52 | 0.18 |
Tumor size (≤ 5 cm vs. >  5 cm) | 0.75–2.39 | 1.34 | 0.33 | 0.40–1.61 | 0.81 | 0.54 |
Tumor stages (T1 + T2 vs. T3 + T4) | 0.40–1.53 | 0.79 | 0.48 | 0.71–3.54 | 1.58 | 0.26 |
Histological type (adenocarcinoma vs. squamous cell carcinoma) | 0.31–1.07 | 0.57 | 0.08 | 0.40–1.80 | 0.85 | 0.68 |
Histologic grade (well/moderate vs. poor/NS) | 0.61–1.90 | 1.08 | 0.80 | 0.62–2.11 | 1.14 | 0.68 |
Lymph node metastasis (negative vs. positive) | 0.77–3.32 | 1.63 | 0.18 | 0.96–4.21 | 2.01 | 0.06 |
Clinical stages (I + II vs. III + IV) | 0.73–4.50 | 3.73 | 0.23 | 0.63–3.46 | 1.48 | 0.37 |
miR-4317 expression level (low vs. high) | 0.14–0.58 | 0.29 | 0.001 | 0.09–0.63 | 0.24 | 0.004 |